1. Introduction {#sec1}
===============

Alzheimer\'s disease (AD) is a severe type of senile dementia, affecting a large portion of elderly people worldwide. It is characterized by profound memory loss and inability to form new memories. The pathological hallmarks of AD are the presence of numerous extracellular deposits, termed senile plaques, and intraneuronal neurofibrillary tangles (NFTs). The degeneration of synapses and neurons in the hippocampus or cerebral cortex is also observed \[[@B1]\]. The major components of NFTs are phosphorylated tau proteins, and that of senile plaques are *β*-amyloid proteins (A*β*Ps). Although the precise cause of AD remains elusive, it is widely accepted that oligomerization of A*β*P and the consequent neurodegeneration might be the cause of neuronal death in AD patients \[[@B2], [@B3]\].

There is considerable interest regarding the mechanism by which A*β*Ps cause neurodegeneration. A*β*Ps have been reported to cause various adverse effects on neuronal survivals, such as the production of reactive oxygen species, the induction of cytokines, the induction of endoplasmic reticulum (ER) stresses, and the abnormal increase in intracellular calcium levels (\[Ca^2+^\]~i~) \[[@B4]\]. These adverse effects are complex and may be interwoven. Of these effects, the disruption of calcium homeostasis could be the earliest and primary event, since Ca^2+^ ions are essential for various neuronal functions. The elevation of \[Ca^2+^\]~i~ induces various apoptotic pathways.

There are several mechanisms that account for A*β*P-induced calcium dyshomeostasis \[[@B5]--[@B7]\]. Of these, we focus on the "amyloid channel hypothesis"---direct insertion into membranes of A*β*P, formation of channels (pores), and disruption of calcium homeostasis *via* unregulated cytotoxic channels may be the molecular basis of its neurotoxicity \[[@B8]--[@B10]\]. Other amyloidogenic disease-related proteins, such as the prion protein or *α*-synuclein, also exhibit similarities in the formation of amyloid channels and in the disruption of calcium homeostasis.

We review here the current understanding of the "amyloid channel hypothesis" based on our recent results and those of other researchers. It is widely recognized that the composition of membrane lipids influences the formation of amyloid channels by affecting the interaction between peptides and membranes. The possible development of new drugs by influencing membrane lipid properties and attenuating amyloid channels for the treatment and prevention of AD is also discussed.

2. Conformational Changes of A*β*P and Its Neurotoxicity {#sec2}
========================================================

A*β*P is a small peptide with 39--43 amino acid residues. It is secreted by the cleavage of the N-terminal of a large precursor protein (amyloid precursor protein; APP) by *β*-secretase (*β*-site APP cleaving enzyme; BACE), followed by the intramembrane cleavage of its C-terminal by *γ*-secretase. This different C-terminal cleavage of APP causes various truncated A*β*Ps, such as A*β*P(1--40), the first 40 amino acid residues, or A*β*P(1--42). Genetic studies of early-onset cases of familial AD indicated that APP mutations and A*β*P metabolism are associated with AD \[[@B11]\]. It was also revealed that mutations in the presenilin genes account for the majority of cases of early-onset familial AD \[[@B12]\]. Presenilins have been revealed to be *γ*-secretases \[[@B13]\], and their mutations influence the production of A*β*P and its neurotoxicity \[[@B14]\].

Yankner et al. reported that A*β*P(1--40) caused the death of cultured rat hippocampal neurons or neurodegeneration in the brains of experimental animals \[[@B15]\]. However, the neurotoxicity of A*β*P has been a subject of much debate because of its peculiar characteristics. A*β*P is a hydrophobic peptide with an intrinsic tendency to self-assemble to form oligomers (aggregates). In the aqueous solution, monomeric form of A*β*P exhibits a random coil structure. Meanwhile, under incubation at 37*۫*°C for several days (*aging*), A*β*Ps form aggregates (oligomers) with *β*-pleated sheet structures. Pike et al. revealed that aged A*β*P(1--40) was considerably more toxic to cultured neurons as compared to freshly prepared A*β*P(1--40) \[[@B16]\]. The neurotoxicity of A*β*P was correlated with their *β*-sheet contents, as observed by circular dichroism (CD) spectroscopy \[[@B17]\]. Jarrett and Lansbury demonstrated that A*β*P forms oligomers by a nucleation-dependent process and that A*β*P(1--42) becomes "seeds" in the aggregates and enhances the oligomerization of A*β*P(1--40)---suggesting the significance of intracellular N- and C-terminal heterogeneity \[[@B18]\].

Recent detailed analysis using size-exclusion chromatography, gel electrophoresis, and atomic force microscopy (AFM) has demonstrated that there are several stable types of soluble oligomers: naturally occurring soluble oligomers (dimers or trimers), ADDLs (A*β*P-derived diffusible ligands), A*β*P globulomers, or protofibrils. Increasing evidence suggests that soluble amyloid oligomers cause synaptic and neuronal degeneration \[[@B19]--[@B21]\]. The identification of toxic A*β*P spices is crucial and has been a subject of scientific debates. Hartley et al. separated aggregated A*β*P(1--40) into low-molecular-weight (mainly monomer), protofibrillar, and fibril fractions by size-exclusion chromatography, and found that the protofibrillar fraction caused marked changes in the electrical activity of cultured neurons and neurotoxicity \[[@B22]\]. Walsh et al. reported that the naturally secreted (derived from the cerebrospinal fluid of AD patients), SDS-stable low-molecular-weight oligomers (dimers, trimers, or tetramers), but not A*β*P monomers or larger aggregates, inhibit long-term potentiation (LTP) and cause the loss of dendritic spines and synapses \[[@B23]\]. Lacor and colleagues reported that A*β*P-derived diffusible ligands (ADDLs) inhibited LTP and exhibited adverse effects on synaptic plasticity, such as abnormal spine morphology, decreased spine density, and decreased synaptic proteins \[[@B24]\]. Recently, Jan et al. found that mixtures of monomeric and heterogenous oligomers A*β*P(1--42) were more toxic than monomeric, protofibrillar fractions or fibril \[[@B25]\]. They demonstrated that A*β*P toxicity depends on the ability to grow and undergo fibril formation of prefibrillar aggregates and monomer. The process of fibril formation and its contribution to toxicity is complicated. Mature fibrils are regarded to be less toxic compared to soluble oligomers \[[@B26], [@B27]\], although there are some cases fibrils direct cause toxicity \[[@B28], [@B29]\]. It is possible that the toxicity of mature fibrils can result from the leakage of toxic short protofibrils or oligomers \[[@B27]\] or from its size-dependent mechanical properties of accumulations in the normal tissues \[[@B30]\].

As synaptic plasticity is crucial for the process of memory formation, synaptic degeneration (synaptotoxicity) is involved in the early stages of AD. Indeed, the number of synapses is strongly correlated with the level of memory impairment in AD patients, rather than the number of senile plaques or NFTs, \[[@B31]\]. Considering that A*β*P is secreted in the cerebrospinal fluid (CSF) of young individuals as well as in aged or dementia patients \[[@B32]\], factors that accelerate or inhibit the oligomerization may play essential roles in the pathogenesis of AD. Various factors, such as the concentration of peptides, the oxidations, mutations, and racemization of A*β*P, pH, composition of solvents, temperature, and trace elements, can influence the oligomerization processes \[[@B33]\]. Among these factors, Al and other trace elements are of particular interest because of the epidemiological link with AD \[[@B34]\].

3. A*β*P-Induced Neurotoxicity and the Disruption of Calcium Homeostasis {#sec3}
========================================================================

There is considerable interest regarding in the mechanism by which A*β*Ps cause neurodegeneration. Of various adverse effects caused by A*β*P, calcium dyshomeostasis could be the earliest and primary adverse event, since Ca^2+^ ions are essential for various key enzymes such as kinases, phosphatases, and proteases. Once neuronal calcium homeostasis was disrupted and \[Ca^2+^\]~i~ was changed, various apoptotic pathways such as calpain and caspase activation occurred, leading to neuronal death. The disruption of calcium homeostasis could trigger the membrane disruption, the formation of reactive oxygen species (ROS), and induce other adverse effects which are often observed after exposure to A*β*P. It is widely known that the increase in \[Ca^2+^\]~i~ induced changes in the number of spines, their morphology, and the number of synapses \[[@B35]\]. Considering that A*β*P and APP coexist in the synapses \[[@B36]\], calcium imbalances in the synaptic compartment could directly influence neuronal activities and cause synaptic impairment (synaptotoxicity). Ca^2+^ is also implicated in the phosphorylation of the tau protein \[[@B37]\] or in APP sequestration \[[@B38]\]. Fibroblasts derived from AD patients exhibited different Ca^2+^ mobilization compared to those derived from age-matched control subjects \[[@B39]\]. Mounting evidence indicates that calcium dysregulation occurs in AD or in A*β*P-intoxicated neurons \[[@B40], [@B41]\].

There are several possible mechanisms by which A*β*Ps interact with neurons and disrupt calcium homeostasis. Demuro et al. reviewed the A*β*P-induced calcium dyshomeostasis and its toxicity in the context of calcium signaling, and outlined three major mechanisms: the activation of some type of cell surface receptors coupled to Ca^2+^ influx, the disruption of membrane integrity, and the direct incorporation into the membrane to create unregulated cytotoxic channels (pores) \[[@B5]\].

A*β*Ps were reported to bind to NMDA (*N*-methyl D-aspartate-)type or AMPA (*α*-amino-3-hydroxy-5-methylisoxazole-4-propionic acid)-type glutamate receptors \[[@B42]\], or nicotinic acetylcholine receptors \[[@B43]\]. All of these receptors were highly Ca^2+^ permeable. Furthermore, A*β*P influences voltage gated Ca^2+^ channels \[[@B44]\] or inositol triphosphate (IP~3~) receptor \[[@B45]\]. It is widely recognized that presenilins are involved in capacitative Ca^2+^ entry, in ER Ca^2+^ signaling, or in mitochondrial Ca^2+^ signaling, and that their mutations affect the calcium-regulated functions \[[@B46]--[@B49]\]. Therefore, disturbances of ER Ca^2+^ stress or mitochondrial Ca^2+^ homeostasis may be involved in the pathogenesis of AD.

4. Channel Formation by A*β*P: Possible Mechanisms of Calcium Dyshomeostasis {#sec4}
============================================================================

In 1993, Arispe et al. first demonstrated that A*β*P(1--40) directly incorporates into artificial planar lipid bilayer membranes and forms cation selective ion channels \[[@B50], [@B51]\]. These "amyloid channels" were revealed to be giant multilevel pores and were permeable to Ca^2+^. Their activity was blocked by Zn^2+^, which is abundantly present in the brain \[[@B52]\]. Other neurotoxic peptide fragments of A*β*P, including A*β*P(25--35) and A*β*P(1--42), were reported to form calcium-permeable pores on artificial lipid bilayers as well as A*β*P(1--40) \[[@B53], [@B54]\]. The characteristics of amyloid channels formed by A*β*P(1--40) and A*β*P(1--42) exhibited similarities: multilevel and giant pores (\~5 nS) and cation (including Ca^2+^) selectivity. The activity of both channels could be blocked by Zn^2+^. Fraser et al. reported that the toxic C-terminal fragment of APP(CT~105~; containing a full length of A*β*P) induced channel currents on membranes of *Xenopus* oocytes \[[@B55]\].

Durell et al. proposed a 3D structural model of amyloid channels obtained from a computer simulation of the secondary structure of A*β*P(1--40) in membranes, which showed 5 to 8 mers aggregating to form pore-like structures on the membranes \[[@B56]\]. Strodel et al. proposed a model of A*β*P(1--42) pores which consist of tetrameric and hexameric *β*-sheet subunits from the observations in NMR \[[@B57]\]. These models are consistent with morphological observations using high-resolution AFM that demonstrated that A*β*Ps form pore-like structures on mica plates or on membranes \[[@B58]--[@B60]\].

A large number of studies have demonstrated that A*β*P directly binds to membranes, causes membrane perturbation or disruption, and induces the increase in permeability to ions (including Ca^2+^) or large molecules \[[@B61]--[@B64]\]. The findings of Demuro et al. are particularly interest in this context \[[@B65]\]. They investigated effects of A*β*P and other amyloid peptides in various aggregation states, and revealed that oligomeric peptides caused the rapid increase in \[Ca^2+^\]~i~ or the membrane disruption, whereas monomers and fibrils did not.

Furthermore, the presence of pore-like structures of A*β*Ps was demonstrated in the neuronal cell membrane of the brains of AD patients and of AD-model mice. Using high-resolution transmission electron microscopy, Inoue observed in situ A*β*P pores in the neuronal cell membrane in AD brains \[[@B66]\]. Kayed et al. reported that the annular protofibrils (APFs) of A*β*P exhibit ring-shaped and pore-like structures \[[@B67]\]. The age-dependent accumulation of APFs was observed on the membranes of AD model mice (APP transgenic mice; APP23) \[[@B68]\].

To determine whether or not A*β*Ps form channels on neuronal cell membranes as well as on artificial lipid bilayers, we employed membrane patches from immortalized hypothalamic neurons (GT1-7 cells). GT1-7 cells are derived from murine hypothalamic neurons by site-directed tumorigenesis and exhibit various neuronal characteristics, such as the extension of neuritis, and the expression of various neuron-specific proteins or receptors \[[@B69]\]. Within 3--30 min of the addition of A*β*P(1--40) to the bath solution, the current derived from the amyloid channels appeared across the excised membrane patches \[[@B70]\]. However, A*β*P(40--1), a peptide bearing the reversed sequence of A*β*P(1--40), did not form any channels. The characteristics of amyloid channels formed on the GT1-7 cell membranes were considerably similar to those observed on artificial lipid bilayers: cation selective, multilevel, voltage independent, and long-lasting. Its channel activity was inhibited by the addition of Zn^2+^, and recovered by a zinc chelator--*o*-phenanthroline. Furthermore, Sepulveda et al. revealed that A*β*P(1--40) formed perforations on membranes excised from hippocampal neurons and induced currents \[[@B71]\]. The effect of A*β*P was similar to that of gramicidin and amphotericin which are commonly used to perforate neuron membranes.

5. Disruption of Calcium Homeostasis Caused by Amyloid Channels {#sec5}
===============================================================

In order to test the validity of the amyloid channel hypothesis, we examined whether A*β*P alters the \[Ca^2+^\]~i~ levels of GT1-7 cells under the same conditions, using a high-resolution multisite video imaging system with calcium-sensitive fluorescent dye, fura-2 \[[@B71]--[@B74]\]. Shown in [Figure 1(a)](#fig1){ref-type="fig"} are pseudocolor images of levels indicating the \[Ca^2+^\]~i~ of GT1-7 cells before and after exposure to A*β*P(1--40). Shortly after exposure to A*β*P(1--40), a marked increase in \[Ca^2+^\]~i~ occurred among many, but not all GT1-7 cells. [Figure 1(b)](#fig1){ref-type="fig"} depicts A*β*P(1--40)-induced temporal changes of the \[Ca^2+^\]~i~ of 50 randomly chosen GT1-7 cells in the same field of view. Furthermore, we compared responses to A*β*P and the related peptides ([Figure 2(a)](#fig2){ref-type="fig"}). Although a marked increase in \[Ca^2+^\]~i~ was caused by A*β*P(1--40) (*line (A)*) or by A*β*P(1--42) (*line (C)*), control peptides such as A*β*P(40-1) caused no remarkable changes (*line (B)*).

As previously discussed, there are several mechanisms that could account for the elevations in \[Ca^2+^\]~i~ induced by A*β*P. However, our detailed quantitative analysis of the A*β*P-induced calcium influx suggests that A*β*P-induced \[Ca^2+^\]~i~ changes occurred *via* unregulated amyloid channels and not by endogenous receptor-mediated pathways. This is supported by 4 major pieces of evidence.

*First*, the A*β*P-induced \[Ca^2+^\]~i~ rise was highly heterogeneous among genetically identical GT1-7 cells. Even in the same field of view, exposure to the same peptide solution produced different change patterns in the \[Ca^2+^\]~i~ levels as shown in [Figure 1(b)](#fig1){ref-type="fig"}. Although A*β*P(1--40) induced an increase in the \[Ca^2+^\]~i~ levels either instantly or after some delay, the magnitude and latency differed. Certain other adjacent cells still did not exhibit any responses. It is possible that the membrane binding of A*β*P is crucial for the cell-to-cell heterogeneity. Simakova and Arispe revealed that the surface phosphatidylserine and the cytosolic ATP levels are important determinants of the binding of A*β*P to membranes \[[@B75]\]. To analyze A*β*P-induced calcium influx quantitatively under the cell-to-cell heterogeneous condition, we compared the peak increase in \[Ca^2+^\]~i~ (Δ\[Ca^2+^\]~i~) induced by A*β*Ps and its latency (the lag between the \[Ca^2+^\]~i~ increase and the time of A*β*P addition) in each cell. This multisite fluorometry system enables the simultaneous long-term observation of temporal changes in \[Ca^2+^\]~i~ of more than 50 neurons. *Second*, the average Δ\[Ca^2+^\]~i~ was increased in a dose-dependent manner of A*β*P, while the average latency decreased (Figures [2(b)](#fig2){ref-type="fig"} and [2(c)](#fig2){ref-type="fig"}). It is unlikely that the dose-dependent decrease in the latency occurs through the receptor-mediated pathways. These features are considerably similar to those observed in relation to peptide channels formed on membranes \[[@B71], [@B76]\]. The concentration of A*β*P required to form amyloid channels is higher (\~*μ*M) than the A*β*P concentration found in the brain. However, it is plausible that it requires a longer period for the lower concentration of A*β*P to cause changes in \[Ca^2+^\]~i~.

*Third*, the A*β*P-induced increase in \[Ca^2+^\]~i~ was not influenced by the addition of the Na^+^ channel blocker (tetrodotoxin), the Ca^2+^ channel blocker (nifedipine), the antagonist of NMDA-type glutamate receptor (D-APV), or the antagonist of *γ*-aminobutyric acid (GABA) receptor (bicuculline) \[[@B77]\].

*Fourth*, D-A*β*P(1--40), A*β*P(1--40) composed of all [D]{.smallcaps}-amino acid residues, also caused the elevation of \[Ca^2+^\]~i~ in a manner similar to A*β*P(1--40) ([Figure 2(a)](#fig2){ref-type="fig"}*line (D)*). This is consistent with the findings of Cribbs et al. suggesting that all-D-enantiomers of A*β*P possess the similar toxicity compared to all-L- A*β*P \[[@B78]\].

Therefore, it is plausible that A*β*P-induced \[Ca^2+^\]~i~ changes occurred through amyloid channels by direct incorporation into membranes, but not through some receptor-mediated pathways.

These results strongly support the hypothetical idea termed "amyloid channel hypothesis," namely, that the direct incorporation of A*β*Ps and the subsequent imbalances of calcium and other ions through amyloid channels may be the primary event in A*β*P neurotoxicity \[[@B8]--[@B10]\].

6. Channel Formation and \[Ca^2+^\]~i~ Influx by Other Amyloidogenic Peptides {#sec6}
=============================================================================

Pore formation-induced cytotoxicity, such as in the cases of certain toxins or venoms, is commonly observed in our biological system. For example, the *α*-toxin of *Staphylococcus aureus,* which is secreted as a single-chain, water-soluble 33 kDa molecule, nonspecifically binds to membranes to form pore-like structures composed of hexamers with *β*-sheet structures, causing Ca^2+^ influx through the pores \[[@B79]\]. Magainin 2, a 26-residue antimicrobial peptide obtained from *Xenopus laevis*, forms transmembrane Ca^2+^-permeable pores on bacterial cell membranes \[[@B80]\]. Other antimicrobial peptides such as melitin (a bee venom composed of 28 amino acids), or antibiotics such as amphotericin and gramicidin were also reported to form transmembrane pores and to cause cell lysis \[[@B81]\]. In this respect, A*β*P and other amyloidogenic proteins might share the similar mechanism with these pore-forming peptides. Indeed, Soscia et al. demonstrated that A*β*P exerts antimicrobial activity against 8 common and clinically relevant microorganisms \[[@B82]\].

Furthermore, electrophysiological and morphological studies have revealed that other disease-related proteins---termed amyloidogenic proteins---exhibit similarities in the formation of amyloid channels as well as A*β*P.

Prion diseases, including human kuru, Creutzfeldt-Jakob disease, and bovine spongiform encephalopathy (BSE), are associated with the conversion of a normal prion protein (PrP^C^) to an abnormal scrapie isoform (PrP^SC^) \[[@B83]\]. The *β*-sheet region of PrP^SC^ is suggested to play a crucial role in its transmissible degenerative processes. A peptide fragment of PrP corresponding to residues 106--126 (PrP106--126) coincides with the proposed *β*-sheet structures and has been reported to cause death in cultured hippocampal neurons \[[@B84]\]. Lin et al. reported that PrP106--126 forms cation permeable pores in artificial lipid bilayers \[[@B85]\]. The activity of PrP channels was also blocked by Zn^2+^. Kourie and Culverson investigated the detailed characteristics of channels formed by PrP106--126, concluding that it was directly incorporated into lipid bilayers and formed cation selective, copper-sensitive ion channels \[[@B86]\]. They also revealed that quinacrine, a potent therapeutic drug, possibly blocks amyloid channels induced by PrP106--126.

The aggregation and fibrillation of *α*-synuclein has been implicated in the formation of abnormal inclusions, termed Lewy bodies, and the etiology of dementia with Lewy bodies (DLB) \[[@B87]\]. Nonamyloid component (NAC), a fragment peptide of *α*-synuclein, accumulates in Alzheimer\'s senile plaques and causes apoptotic neuronal death \[[@B88]\]. Lashuel et al. demonstrated by electron microscope observation that *α*-synuclein forms annular pore-like structures \[[@B89]\].

The elongation of a polyglutamine-coding CAG triplet repeat in the responsible genes is based on the pathogenesis of triplet-repeat disease such as Huntington\'s disease or Machado-Joseph disease \[[@B90]\]. Hirakura et al. reported that polyglutamine formed ion channels in lipid bilayers \[[@B91]\]. Human amylin (IAAP, islet amyloid peptide) forms amyloid fibrils, accumulates in the islet of patients of type 2 *diabetes mellitus*, and causes cytotoxicity in islet cells or in cultured hippocampal neurons. However, rat amylin did not cause cytotoxicity nor form *β*-sheet structures, in spite of the 95% similarity in the amino acid sequence \[[@B92]\]. Mirzabeko et al. revealed that human amylin formed ion channels on liposomes, but rat amylin did not \[[@B93]\]. Calcitonin is a 32-amino acid polypeptide hormone, which is produced by the thyroid C-cells. It is involved in calcium homeostasis and is associated with medullary carcinoma of the thyroid \[[@B94]\]. Using transmission electron microscopy (TEM) observation on liposome, Diociaiuti et al. found that calcitonin oligomers exhibit annular pore-like structures \[[@B95]\]. Lal et al. investigated the oligomerization and conformational changes of A*β*P, synuclein, amylin, and other amyloidogenic proteins using gel electrophoresis and AFM imaging, and demonstrated that these amyloidogenic proteins form annular channel-like structures on bilayer membranes \[[@B96]\].

We have demonstrated that these amyloidogenic peptide also cause the elevations in \[Ca^2+^\]~i~ as well as A*β*P ([Figure 3(a)](#fig3){ref-type="fig"}). A marked increase in \[Ca^2+^\]~i~ was caused by PrP106--126 (*line (A)*), human amylin (*line (C)*), NAC (*line (E)*) and A*β*P(1--40) ([Figure 2(a)](#fig2){ref-type="fig"}, *line (A)*) or pore-forming antimicrobial peptide magainin 2 (*line (F)*). However, control peptides such as peptide with random sequence of PrP106--126 (scramble PrP106--126) (*line (B)*) and rat amylin (*line (D)*) caused no remarkable changes. Furthermore, PrP106--126 and human amylin, as well as A*β*P(1--40), cause disruption of liposome membranes and induce dye release ([Figure 3(b)](#fig3){ref-type="fig"}).

These diseases are included in "conformational disease" (protein misfolding disease)---the conformational change of amyloidogenic proteins is suggested to be an important determinant of its toxicity and, consequently, the development of the disease \[[@B97]\]. The disease-related amyloidogenic proteins exhibit similarities in the formation of *β*-pleated sheet structures, abnormal deposition as amyloid fibrils in the tissues, and introduction of apoptotic degeneration. As shown in [Table 1](#tab1){ref-type="table"}, these amyloidogenic proteins exhibit similarities in the direct incorporation into membranes, formation of calcium-permeable ion channels, and induction of abnormal elevation of \[Ca^2+^\]~i~. It is strongly suggested that disruption of calcium homeostasis *via* unregulated amyloid channels formed by these disease-related proteins may be the molecular basis of neurotoxicity of these diseases.

7. Role of Membrane Lipids in the Formation of Amyloid Channels {#sec7}
===============================================================

It is widely accepted that the direct incorporation of peptides into membranes and consequent channel formation is strongly affected by the membrane lipid composition, particularly the net charges of membrane surfaces and membrane fluidity. Several A*β*P residues (such as Arg^5^, Lys^16^, and Lys^28^) have a positive charge at neutral pH, and therefore, A*β*P has an affinity for negatively charged phospholipids, such as phosphatidylserine (PS) or phosphatidylglycerol (PG), but not for neutral phospholipids, such as phosphatidylcholine (PC) \[[@B98]\]. However, membrane phospholipid distribution is asymmetrical in mammals: neutral lipids (PC, etc.) usually exist on the outer surfaces of plasma membranes, whereas negatively charged phospholipids (PS, etc.) exist in the inner surfaces of the membranes. Thus, the binding of A*β*P to neuronal membrane surface may seldom occur in normal and young brains.

Further influencing the binding of A*β*P to membranes are gangliosides---sialic-acid-bearing glycophospholipids. Both APP and A*β*P are localized in detergent-insoluble, cholesterol-, sphingomyelin-, and ganglioside-rich lipid microdomains, termed rafts \[[@B99]\]. Yanagisawa et al. first demonstrated the existence of membrane-bound A*β*P tightly bound to GM1 gangliosides in the brains of AD patients \[[@B100]\]. A*β*P binds to GM1 gangliosides in raft-like membranes *in vitro,* and GM1-bound A*β*P behave as a "seed" and accelerate the oligomerization of A*β*P \[[@B101]\]. Numerous studies have indicated the implication of gangliosides in the oligomerization and the binding to the membrane of A*β*P \[[@B102]--[@B104]\].

We have observed the deposition of A*β*P(1--40) on ganglioside (GM1)/phospholipid (dipalmitoil phosphatidyl choline; DPPC) monolayers by AFM imaging ([Figure 4](#fig4){ref-type="fig"}). GM1-DPPC membranes exhibit distinctive, island-like GM1 domains embedded in the DPPC matrix \[[@B105], [@B106]\]. Aged A*β*P(1--40) deposited and tightly bound to the membrane surfaces and exhibited the damaged structures of membranes, meanwhile freshly prepared A*β*P showed few changes.

We have previously demonstrated that A*β*P causes a marked increase in \[Ca^2+^\]~i~ in a large proportion of long-term (30--35 days *in vitro*; DIV) cultured hippocampal neurons. However, few or no changes were observed in \[Ca^2+^\]~i~ in short-term (8 DIV) cultures ([Figure 5(a)](#fig5){ref-type="fig"}) \[[@B107]\]. After several days of exposure to sublethal levels of A*β*P(1--40) to long-term cultured neurons, A*β*P binds to some restricted hippocampal neurons and exhibits dotlike depositions on the somata and dendrites. Meanwhile, there is no detectable A*β*P deposition on the surfaces of neighboring neurons, despite the morphological similarities of these neurons ([Figure 5(b)](#fig5){ref-type="fig"}). Malchiodi-Albedi et al. found that lipid rafts increased during the maturation of culture periods of primary cultured rat hippocampal neurons \[[@B108]\]. They demonstrated that Calcitonin, an amyloidogenic peptide, causes \[Ca^2+^\]~i~ changes in mature raft-containing neurons, but not in immature cultured neurons. Williamson et al. found that A*β*P was not uniformly distributed over the neuronal processes, and was colocalized with GM1 ganglioside \[[@B109]\]. These features are consistent with our results, and it is possible that gangliosides in lipid rafts may regulate the binding of A*β*P into membranes and its neurotoxicity.

It is widely accepted that cholesterol enhances membrane stiffness, decreases membrane fluidity, and inhibits pore formation by pore-forming peptides \[[@B110]\]. Lin and Kagan found that cholesterol inhibits channel formation by A*β*P \[[@B111]\]. Cholesterol blocks A*β*P-induced elevations in \[Ca^2+^\]~i~ \[[@B41], [@B72]\], aggregation of A*β*P-containing liposomes \[[@B112]\], and A*β*P cytotoxicity \[[@B112], [@B113]\]. Moreover, cholesterol attenuates A*β*P-induced membrane-disordering effects and calcium increase \[[@B114]\]. Considering that apolipoprotein E, involved in cholesterol transport and metabolism, is present in the senile plaques and NFTs in AD brains and its polymorphism is a risk factor of AD \[[@B115]\], the implication of cholesterol in AD pathogenesis is crucial.

To determine the implications of membrane properties in the formation of amyloid channels, we tested the effects of several lipophilic substances, which modulate membrane properties, on A*β*P-induced \[Ca^2+^\]~i~ elevations \[[@B74], [@B107]\]. Phloretin, a plant-derived flavonoid, decreases membrane dipole potential, and inhibits the electrostatic interaction between A*β*P and membrane lipids, and attenuates A*β*P-induced neurotoxicity \[[@B116]\]. Meanwhile, 6-ketocholestanol increases the magnitude of the membrane dipole potential and decreases membrane fluidity \[[@B117]\]. [Figure 6](#fig6){ref-type="fig"} shows that the preadministration of phloretin and cholesterol markedly inhibited A*β*P-induced \[Ca^2+^\]~i~ elevations; meanwhile, 6-ketocholestanol did not cause significant changes, despite the structural similarity to cholesterol. Therefore, as expected from other findings, the net charges of membrane surfaces and the membrane fluidity play crucial roles in the elevations of \[Ca^2+^\]~i~ caused by A*β*P.

Furthermore, numerous studies have demonstrated that gangliosides and cholesterol are implicated in the channel formation of other amyloidogenic proteins. Lipid rafts are considered to be the compartment where the conformational change of PrP occurs \[[@B118]\]. Gangliosides influence the *β*-sheet formation of PrP106--126 \[[@B119]\] and human amylin \[[@B120]\], or the channel formation of *α*-synuclein \[[@B121]\]. Cholesterol also inhibits channel formation by human amylin \[[@B122]\].

8. Possible Candidate for the Treatment of AD {#sec8}
=============================================

The search for protective agents against A*β*P neurotoxicity is of great importance. Such agents include inhibitors of A*β*P oligomerization, inhibitors of BACE or *γ*-secretase, A*β*P vaccines, and chelators of trace metals; all have been proposed to be effective in the treatment of AD.

Here, we have focused on substances that inhibit the formation of amyloid channels. As discussed, the elevation of \[Ca^2+^\]~i~ by permeation through amyloid channels is considered to be the primary event of A*β*P neurotoxicity; therefore, such compounds could serve as the seed of new effective drugs with fewer adverse effects.

Zn^2+^ ion, which is abundant in vesicles of presynaptic terminals and is secreted into synaptic clefts with neuronal excitation, inhibits the currents induced by amyloid channels \[[@B52], [@B54], [@B70]\]. Zn^2+^ binds to His residues of A*β*P: Arispe et al. found that histidine-related peptide derivatives such as His-His or polyhistidine are effective in the inhibition of amyloid channels, the attenuation of A*β*P-induced \[Ca^2+^\]~i~ changes, and the protection of neurons from A*β*P toxicity \[[@B123], [@B124]\]. They developed several small amphiphilic pyridinium derivatives which inhibit formation of A*β*P channels and its neurotoxicity \[[@B8], [@B125]\].

In line with the search for protective agents, we have screened compounds, which influence membrane properties and inhibit formations of amyloid channels, by observing the A*β*P-induced Ca^2+^ influx. Among those tested, we found that several lipophilic substances, such as 17*β*-estradiol, 17*α*-estradiol, and neurosteroids (including dehydroepiandrosterone \[DHEA\], DHEA sulfate \[DHEA-S\], and pregnenolone) significantly inhibit A*β*P-induced \[Ca^2+^\]~i~ elevation \[[@B74], [@B107]\]. 17*β*-estradiol, a female hormone, is neuroprotective and affects membrane fluidity \[[@B126]\]. Considering that both 17*β*-estradiol and 17*α*-estradiol inhibit A*β*P-induced \[Ca^2+^\]~i~ elevation, the inhibition may not depend on their genomic actions but on their membrane-modifying effects. Neurosteroids are steroid hormones synthesized *de novo* in the central nervous system from cholesterol or from peripheral steroid precursors \[[@B127]\]. Several lines of evidence suggest that neurosteroids modulate various functions of the brain and exhibit neuroprotective activities \[[@B128]\]. Considering that concentrations of plasma DHEA are reduced in AD patients \[[@B129]\], the implication of neurosteroids in the pathogenesis of AD may be important.

9. Amyloid Channel Hypothesis {#sec9}
=============================

Based on the results of our studies, together with those of other studies, we propose the following hypothetical scheme: that unregulated calcium influx *via* amyloid channels may underlie the molecular mechanism of A*β*P neurotoxicity and the pathogenesis of AD ([Figure 7](#fig7){ref-type="fig"}).

A*β*Ps are normally secreted from APP, which exists in the synapse, into the cerebrospinal fluid or synaptic clefts. Secreted A*β*Ps are degraded proteolytically by proteases, such as neprilysin \[[@B130]\], within a short period. However, upregulation of the A*β*P secretion from APP, or an increased ratio of A*β*P(1--42) to A*β*P(1--40) may render A*β*Ps liable to be retained in the brain. Mutations of APP or presenilin gene promote this process. The binding of A*β*P to neuronal membranes is the important determinant for its neurotoxicity. Since A*β*P seldom binds to normal neuronal membranes with neutral phospholipids such as PC usually existing on the outer surfaces of plasma membranes, it would be less likely to occur in the brains of normal and young subjects. However, when the asymmetrical distribution is disrupted by apoptotic conditions or aging and negatively charged phospholipids such as PS appear on the outer membrane surfaces, A*β*Ps can bind to membrane surfaces ([Figure 7(a)](#fig7){ref-type="fig"}). Furthermore, considering that A*β*Ps have affinity to PS in inner membrane surfaces, the intraneuronal accumulation of A*β*Ps may be more toxic \[[@B131]\]. Gangliosides also contribute to the net charge of the outer membrane surface and to the binding to A*β*Ps ([Figure 7(b)](#fig7){ref-type="fig"}). Microcircumstances on the membranes, such as lipid rafts, provide suitable locations which facilitate this process from (A) to (B). After incorporation into the membrane, the conformation of A*β*Ps change and the accumulated A*β*Ps aggregate on the membranes. The ratio of cholesterol to phospholipids in the membrane may alter membrane fluidity, thereby affecting these processes. Finally, aggregated A*β*P oligomers form ion channels leading to the various neurodegenerative processes ([Figure 7(C)](#fig7){ref-type="fig"}).

The velocity of channel formation will be regulated by the binding of A*β*P on membranes and its concentration. Considering that soluble oligomers are more toxic compared to monomer or fibrils \[[@B26], [@B27], [@B65]\], it is provable that A*β*P oligomerization *in vitro* accelerates the velocity from (A) to (B), and enhances the formation of tetrameric or hexameric pores on membranes. Indeed, O\'Nuallain et al. demonstrated that A*β*P dimers formed toxic protofibrils more rapidly compared to monomer \[[@B132]\]. However, the proposed structures of A*β*P channels in membrane mimic conditions are not always similar to the structures formed in the solution such as protofibrils or soluble oligomers. Thus, the conformational changes in membranes may also be significant.

These processes required for channel formation ((A) to (C)) may require a long life span in general and determine the rate of the entire process. Unlike endogenous Ca^2+^ channels, these A*β*P channels are not regulated by usual blockers. Thus, once formed on membranes, a continuous flow of \[Ca^2+^\]~i~ is initiated.

Disruption of calcium homeostasis triggers several apoptotic pathways and promotes numerous degenerative processes, including free radical formation and tau phosphorylation, thereby accelerating neuronal death. The source of Ca^2+^ may be from extracellular or intracellular Ca^2+^ store (ER or mitochondoria). Considering that presenilins are involved in the capacitive calcium entry, in Ca^2+^ homeostasis in ER or in mitochondoria \[[@B46]--[@B49]\] and the implication of ER stress in AD and other neurodegenerative diseases \[[@B133]\], mutations of presenilins may influence these pathways. Free radicals also induce membrane disruption, by which unregulated calcium influx is further amplified. The disruption of calcium homeostasis influences the production and processing of APP. Thus, a vicious spiral of neurodegeneration is initiated. Meanwhile, zinc ions, which are secreted into synaptic clefts in a neuronal activity-dependent manner, inhibit A*β*P-induced Ca^2+^ entry, and thus have a protective function in AD.

This hypothesis explains the long delay in AD development; AD occurs only in senile subjects despite the fact that A*β*Ps are also normally secreted in younger or in normal subjects. AD is multifactorial disease. Various environmental factors, such as foods (cholesterol contents) or trace metals, as well as genetic factors will influence these processes and contribute to AD pathogenesis. The amyloid channel hypothesis could explain effects of environmental factors such as cholesterol and other various aspects of AD pathogenesis and may aid in improving a precise understanding of AD and in the development of drugs for AD treatment. Although the findings of channel-like structures *in vivo* \[[@B66], [@B68]\], it is difficult to determine whether these amyloid channels really exist in the brains of AD patients. Therefore, further *in vivo* studies are necessary.
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AD:

:   Alzheimer\'s disease,

A*β*P:

:   Alzheimer\'s *β*-amyloid protein

AFM:

:   Atomic force microscopy

AMPA:

:   *α*-amino-3-hydroxy-5-methylisoxazole-4- propionic acid
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:   Amyloid precursor protein

D-APV:

:   2-amino-5-phosphonovalerate

BACE:

:   *β*-site APP cleaving enzyme

ER:

:   Endoplasmic reticulum
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:   Long-term potentiation
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:   Neurofibrillary tangles

\[Ca^2+^\]~i~:

:   Intracellular calcium levels
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:   N-methyl-D-aspartate

ROS:

:   Reactive oxygen species

SDS:

:   Sodium dodecyl sulfate
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:   Tetrodotoxin.

![Effects of A*β*P on temporal changes of \[Ca^2+^\]~i~. (a) Pseudocolor images of \[Ca^2+^\]~i~ during exposure to A*β*P(1--40) in GT1-7 cells. A solution of A*β*P(1--40) (10 *μ*M) was applied onto fura-2-loaded GT1-7 cells. Temporal changes of fluorescence intensities corresponding to increases in \[Ca^2+^\]~i~ were analyzed. (A) 1 min before exposure to A*β*P(1--40); (B) 20 sec after exposure; (C) 5 min after exposure. (b) Temporal changes of randomly chosen 50 GT1-7 cells in the same field of view before and after the exposure to A*β*P(1--40) are depicted. The arrow indicates the time of peptide addition.](IJAD2011-304583.001){#fig1}

![Characteristics of A*β*P-induced elevations in \[Ca^2+^\]~i~. (a) Typical time course of \[Ca^2+^\]~i~ prior to 2 min and after 3 min of the application of the peptide is depicted. Concentration is 10 *μ*M for all peptides used. (A) A*β*P(1--40); (B) A*β*P(40-1); (C) A*β*P(1--42); (D) D-A*β*P(1--40). The arrow indicates the time of peptide addition. (b) and (c) Dose-dependence of the increase in \[Ca^2+^\]~i~. Typical responses of \[Ca^2+^\]~i~ in cultured neurons following exposure to various concentrations of A*β*P(1--40) (2.5\~10 *μ*M). The peak increase in \[Ca^2+^\]~i~ (Δ\[Ca^2+^\]~i~) in each cell (b) and the latency after exposure to A*β*P(1--40) were analyzed in more than 50 neurons in field of view (360 × 420 *μ*m) cultured neurons (mean ± S.E.M., *n* = 300).](IJAD2011-304583.002){#fig2}

![Effects of amyloidogenic proteins on membrane disruption and \[Ca^2+^\]~i~ elevations. (a) Effects of amyloidogenic proteins and their analogues on \[Ca^2+^\]~i~. Typical time course of \[Ca^2+^\]~i~ prior to 2 min and after 3 min of the application of the peptide is depicted. Concentration is 10 *μ*M for all peptides used. (A) PrP106--126; (B) scramble PrP106--126; (C) human amylin; (D) rat amylin; (E) NAC; (F) magainin 2. The arrow indicates the time of peptide addition. (b) Membrane disruption by amyloidogenic peptides. A*β*P(1--40)  (closed circle), PrP106--126 (closed square), and human amylin (open circle) (each 10 *μ*M) were added to negatively charged liposomes containing carboxyfluorescein. The ratio of DPPC (dipalmitoil phosphatidyl choline): CHOL (cholesterol): DPPG (dipalmitoil phosphatidyl glycerol) in the liposome was 3 : 4 : 3. The temporal changes of the fluorescence intensity were monitored. The ratio of the released fluorescent dye (carboxy fluoresein; CF) compared to the total amount of CF was described as the percentage of membrane disruption.](IJAD2011-304583.003){#fig3}

![AFM images of A*β*P(1--40) on monolayer membranes. Lipid monolayer membranes composed by DPPC (a) or ganglioside GM1-DPPC (dipalmitoil phosphatidyl choline) (b)\~(d) were prepared by bath sonication and reconstitution on mica plates. The ratio of GM1:DPPC was 8 : 2. AFM images were obtained after the exposure to freshly prepared A*β*P(1--40) (c) or aged A*β*P(1--40) (d). Scale area: 1.5 × 1.5 *μ*m.](IJAD2011-304583.004){#fig4}

![(a) Maturation-dependent increase in A*β*P-induced \[Ca^2+^\]~i~ changes in primary cultured neurons. (b) Heterogeneous affinity of A*β*P to mature cultured hippocampal neurons. Long-term cultured rat hippocampal neurons were exposed to 1 *μ*M of A*β*P(1--40) at 29 DIV and fixed after 4 days. Neurons were double immunostained by anti-MAP2 antibody (Texas Red, red) and anti-A*β*P antibody (FITC, green), and observed by Laser confocal microscopy. Scale bar represents 50 *μ*m. (modified from \[[@B100]\]).](IJAD2011-304583.005){#fig5}

![Effect of membrane charges and fluidity on A*β*P-induced \[Ca^2+^\]~i~ rise. The solutions of phloretin (PH), 6-ketocholestanol (KC), and cholesterol (Chol) were preadministrated on GT1-7 cells; and A*β*P-induced \[Ca^2+^\]~i~ rise was analyzed. Data are mean ± S.E.M., *n* = 250, \*\**P* \< .001. (modified from \[[@B67]\]).](IJAD2011-304583.006){#fig6}

![Hypothesis concerning amyloid channels and pathogenesis of Alzheimer\'s disease. A*β*Ps are secreted from APP in synapses, directly incorporated into membranes. The possible hypothetical scheme of the formation of oligomeric amyloid channels is depicted. Details are shown in the text.](IJAD2011-304583.007){#fig7}

###### 

Characteristics of amyloidogenic proteins and the related peptides.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease                                  Amyloidogenic protein or its fragment peptide and the primary sequence   *β*-sheet formation   Cytotoxicity   Channel formation   \[Ca^2+^\]~i~ rise
  ---------------------------------------- ------------------------------------------------------------------------ --------------------- -------------- ------------------- --------------------
  Alzheimer\'s disease                     *AβP(1--40)*                                                                                                                      

   DAEFRHDSGYEVHHQKLVFFAE                  \+                                                                       \+                    \+             \+                  

   DVGSNKGAIIGLMVGGVV                                                                                                                                                        

  *AβP(40-1)*                                                                                                                                                                

   VVGGVMLGIIAGKNSGVDEAFFV                 --                                                                       --                    --             --                  

   LKQHHVEYGSDHRFEAD                                                                                                                                                         

  *AβP(25-35)*                                                                                                                                                               

   DVGSNKGAII                              \+                                                                       \+                    \+             \+                  

  *AβP(1--42)*                                                                                                                                                               

   DAEFRHDSGYEVHHQKLVFFAEDV                \+                                                                       \+                    \+             \+                  

   GSNKGAIIGLMVGGVVIA                                                                                                                                                        

                                                                                                                                                                             

  Prion disease                            *PrP106--126 (prion protein fragment)*                                                                                            

   KTNMKHMAGAAAAGAVVGGLG                   \+                                                                       \+                    \+             \+                  

  *Scramble PrP106--126*                                                                                                                                                     

   NGAKALMGGHGATKVMVGAAA                   --                                                                       --                    --             --                  

                                                                                                                                                                             

  Parkinson\'s disease\                    *α-synuclein NAC* (a *fragment of α-synuclein)*                                                                                   
  (DLB; diseases with Lewy bodies)                                                                                                                                           

   EQVTNVGGAVVTGVTAVAQKTVEGAGSIAAA  TGFV   \+                                                                       \+                    \+             \+                  

                                                                                                                                                                             

  Triplet-repeat disease                   *Polyglutamine*                                                                                                                   

   QQQQQQQQ---                             \+                                                                       \+                    \+             n.d.                

                                                                                                                                                                             

  Diabetes mellitus                        *Human amylin*                                                                                                                    

   KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY   \+                                                                       \+                    \+             \+                  

  *Rat amylin*                                                                                                                                                               

   KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTY   --                                                                       --                    --             --                  

                                                                                                                                                                             

  Medullary carcinoma of the thyroid       *Calcitonin*                                                                                                                      

   CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP        \+                                                                       \+                    \+             \+                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

n.d.: not determined.
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